Stem Cell Articles

[manouli]

UCLA Stem Cell Scientists Awarded $49.2 Million
November 1, 5:07 PMLA Headlines ExaminerKasey Jones


Within four years we may have an answer for some of the deadliest diseases such as sickle cell disease, HIV/AIDS, and ovarian, colorectal, and brain cancers.

A total of 14 grants, over $250 million, were awarded throughout the state of California by the California Institute for Regenerative Medicine (CIRM).

The CIRM awarded Drs. Irvin Chen, Donald Kohn and Dr. Dennis Slamon grants totalling $49.2 million.

The three UCLA Broad Stem Cell Research Center (BSCRC) scientists will be able to take their stem cell research and translate it to new bedside therapies by 2014 or sooner.

On November 2, 2004 Californians approved Proposition 71, the California Stem Cell Research and Cures Initiative. The initiative makes conducting stem cell research a state constitutional right. It also:

continue.....

http://www.examiner.com/x-28270-LA-H...ed-492-Million

[manouli]

Company - EANS-News: DEWB Investment Holding NOXXON Announces Initiation of First-in-Human Clinical Trial with Hematopoietic Stem Cell Mobilizing Spiegelmer® NOX-A12

Corporate news transmitted by euro adhoc. The issuer/originator is solely responsible for the content of this announcement. Company Information Berlin, Germany, November 02, 2009 (euro adhoc) - NOXXON Pharma AG, the biopharmaceutical company focusing on the development of novel ...
Corporate news transmitted by euro adhoc. The issuer/originator is solely responsible for the content of this announcement.

Company Information

Berlin, Germany, November 02, 2009 (euro adhoc) - NOXXON Pharma AG, the biopharmaceutical company focusing on the development of novel drugs based on its unique proprietary Spiegelmer® technology, announced today the successful initial dosing of healthy volunteers in a first-in-human clinical trial with Spiegelmer® NOX-A12. NOX-A12 is NOXXON´s second drug candidate entering the clinical stage of development within only five months.

more...

http://www.direktbroker.de/news-kurs...+Inve/20661227

[manouli]

US stem cell firm acquires China Biopharmaceuticals



Singapore, Nov 2, 2009: NeoStem, a US-based developer of stem cell therapies, has completed the acquisition of China Biopharmaceuticals (CHBP). The shareholders of CHBP approved the acquisition at a meeting held on November 1, 2009.


Robin Smith, MD and CEO of NeoStem, said, “This acquisition has been eagerly anticipated by supporters of both NeoStem and CHBP. At NeoStem, we are very excited to complete this transaction and begin our collaboration with Suzhou Erye Pharmaceutical, CHBP's primary operating subsidiary. This milestone adds in a significant way to NeoStem's existing business and intellectual property platform and assists in opening international access for the company and its clientele to advanced stem cell technologies, preeminent physicians, and innovative therapies for a growing number of conditions.”





more...

http://www.biospectrumasia.com/conte...09CHN11119.asp

[manouli]

StemEx(R) Noted as a Reliable Investigational Product of an Expanded Population of Stem Cells at Umbilical Cord Blood Symposium in Israel
StemEx is Currently Being Studied in The International ExCell Phase II/III Trial as a Treatment for Leukemia and Lymphoma


HERZLIYA, Israel, November 2 /PRNewswire/ -- At a symposium today in Herzliya entitled Umbilical Cord Blood: An Alternative for Bone Marrow Transplantation in Adults, bone marrow transplantation experts Professor Patrick Stiff and Professor Guillermo Sanz addressed participants on the current challenges presented by bone marrow transplantation and the importance of investigating cord blood as an alternative source for treating patients with leukemia and lymphoma.

Professor Stiff is the Director of the Cardinal Bernardin Cancer Center and the Coleman Professor of Hematology/Oncology at Loyola University School of Medicine in Chicago. Professsor Sanz is the Head of the Dept. of Bone Marrow Transplantation; Dept. of Hematology, Hospital Universitario La Fe, Valencia, Spain. The symposium was sponsored by the Gamida Cell-Teva Joint Venture.

more....

http://dallas.bizjournals.com/dallas...9/11/02/UKM026

[Duran]

RNL BIO's success of stem cell treatment - Chloe, a college student who was diagnosed with autoimmune hearing loss regained her hearing after two months of receiving stem cell treatment.

SEOUL, South Korea, Nov. 4 /PRNewswire-FirstCall/ -- RNL BIO Co., Ltd, (www.rnl.co.kr) a leading biopharmaceutical company specialized in adult stem cell therapeutics announced today that it treated an American college student who was suffering from autoimmune hearing loss and she gained her hearing back in two months after treatment.

RNL BIO is a premier biotechnology company focused on the research and development of adult derived stem cell therapies. RNL has two therapies in Phase II clinical trials for Buerger's Disease as well as Osteoarthritis and one phase I trial for spinal cord injury. RNL is a publicly traded company on the Korean Stock Exchange (Code 003190) and is expanding its operations throughout the world.

http://www.earthtimes.org/articles/s...,1027683.shtml

[manouli]

Public forum at Union University discusses stem cell research

By TRACIE SIMER
tsimer@jacksonsun.com
• November 7, 2009

A new documentary film features scientists, college students, people healed through modern medicine and medical ethicists. The topic they have in common - embryonic stem cell research.

"Lines That Divide" outlines the stem cell research debate, said Jennifer Lahl, founder and national director of the Center for Bioethics and Culture Network.

Union University is showing the film at 7 p.m. Thursday in the Carl Grant Events Center. The Carl F.H. Henry Center for Intellectual Discipleship at Union is hosting the event.

Lahl, the film's associate producer, has more than 25 years experience as a pediatric critical care nurse, hospital administrator and senior-level nursing manager. She said there is still debate taking place over issues of using human embryos for research, among other things.

"There's also human cloning and the targeting and exploiting of young women to give their eggs for research," she said.

The title for "Lines that Divide" is a combination play on the fact that stem cells divide to grow, and the film discusses political and religious lines that divide people on ethics and science, Lahl said.

"Science tells what we can do, ethics says we what should do," she said.

Producers intentionally interviewed people on all sides of the stem cell research debate: those who are pro-cloning, those who say they must do this research; feminists who are outraged that women are being targeted; patient testimonies; and patients treated with their own adult stem cells.

"We talk about where the advances are happening now," she said. "We let all sides tell their point of view. We didn't want to make a documentary that just said, 'This is what we think.' We let the story unfold and play out."

After a year and a half of interviews, script writing and editing, the film was released in May. It has been shown on TV stations nationwide and premiered at the National Press Club in Washington, D.C., Lahl said.

One major venue has been college campuses, where female students are asked to donate their eggs.

continue....

http://www.jacksonsun.com/article/20...TYLE/911070302

[manouli]

Cord Blood Reverses Cerebral Palsy in Colorado Girl
Monday, November 09, 2009
By Jessica Ryen Doyle



Chloe Levine was born seemingly perfect — she was the happy and healthy baby her parents had dreamed of.

But by the time she was 9 months old, Chloe was not reaching the milestones her older sister Shayla had met at that age.

Chloe’s right hand was constantly clenched in a tight fist – she couldn’t even hold her bottle. And she wasn’t able to crawl; she would "shuffle" her body across the floor in a seated position, her mother, Jenny, recalls.

Soon after Chloe’s first birthday, the Levines, who live in Denver, learned their daughter had suffered a stroke in utero and had become afflicted with cerebral palsy.

VIDEO: Click here to learn more about Chloe Levine

read....

http://www.foxnews.com/story/0%2C293...3265%2C00.html

[manouli]

Stem cell samples sought from black community


By Jennifer Fong, Edmonton JournalNovember 9, 2009Comments (2)

Tefferi Wendu took four cotton-tipped sticks and swabbed his cheeks, twice on each side. The whole process took less than 10 minutes, but by the end of it, the 25-year-old was on his way to saving a life.

Tiny cell samples collected on the swabs could help match Wendu with one of more than 800 patients in Canada who currently need a stem-cell transplant.

Wendu was one of about 30 people who the OneMatch Stem Cell and Marrow Network swabbed and registered on Saturday at a bone-marrow transplant and leukemia awareness event at the Africa Centre in northwest Edmonton. The event, organized in memory of Edmontonian Nega Alem Abraham, was meant to educate members of the local black community about the importance of stem-cell donations.

Stem cells are blood-forming cells found in bone marrow, circulating blood and umbilical cords. Transplants are often used to treat blood cancers such as leukemia, lymphoma and myeloma.

more...

http://www.edmontonjournal.com/healt...393/story.html

[manouli]

Scientists Successfully Reprogram Blood Cells
Published on 9 November 2009, 13:44 Last Update: 3 hour(s) ago by Insciences

CINCINNATI – Researchers have transplanted genetically modified hematopoietic stem cells into mice so that their developing red blood cells produce a critical lysosomal enzyme preventing or reducing organ and central nervous system damage from the often-fatal genetic disorder Hurler syndrome.

The research team from Cincinnati Children's Hospital Medical Center reports its preclinical laboratory results this week in the early edition of Proceedings of the National Academy of Sciences.

The study suggests a new approach to molecular gene therapy and a much-needed improved treatment option for children with Hurler syndrome, said Dao Pan, PhD, a researcher in the division of experimental hematology/cancer biology at Cincinnati Children's and the study's principal author. It also is the first study to demonstrate that developing red blood cells can be used to produce lysosomal enzymes.

"The idea behind this is gene insertion so that after one treatment a person would be cured," said Pan, who also is an assistant professor of pediatric at the University of Cincinnati College of Medicine. "In the mouse models receiving this treatment, the pathology of the peripheral organs tested was completely normalized. And although not as complete, we also saw significantly improved neurological function and brain pathology."


more...

http://insciences.org/article.php?article_id=7490

[manouli]

R.I. Hospital receives $11-million stem-cell grant

01:00 AM EST on Tuesday, November 10, 2009

By Felice J. Freyer

Journal Medical Writer

Rhode Island Hospital has won an $11-million federal grant for stem-cell research.

Awarded to Dr. Peter Quesenberry, the hospital’s director of hematology/oncology, the five-year grant will pay for the development of a stem-cell research center that will examine mechanisms of cell repair and, it is hoped, boost the careers of young researchers.

The Center of Biomedical Research Excellence grant, from the National Center for Research Resources of the National Institutes of Health, will “help us to assemble a group of outstanding, talented investigators who excel in these areas,” Quesenberry said. “Those investigators can then serve as mentors to young, up-and-coming researchers, who we can recruit and then retain right here at this research center.”

more...

http://www.projo.com/news/content/ST...1.3a699f6.html